(Total Views: 460)
Posted On: 08/10/2024 2:49:20 PM
Post# of 155734
I'd say the carboplatin combo....
CytoDyn, Inc. is a biotechnology company that has conducted clinical trials combining carboplatin with leronlimab to treat metastatic triple-negative breast cancer (mTNBC). In July 2021, CytoDyn announced promising preliminary results from the phase 1b/2 trial, which involved 30 patients. The FDA also granted CytoDyn fast track designation for leronlimab in 2019.
CytoDyn, Inc. is a biotechnology company that has conducted clinical trials combining carboplatin with leronlimab to treat metastatic triple-negative breast cancer (mTNBC). In July 2021, CytoDyn announced promising preliminary results from the phase 1b/2 trial, which involved 30 patients. The FDA also granted CytoDyn fast track designation for leronlimab in 2019.
(1)
(0)
